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CASE PRESENTATION
A 42-year-old Caucasian male was initially admitted with
generalized weakness, malaise, poor oral intake, and
occasional nausea and vomiting for 3 weeks.
There was no history of gross hematuria or shortness of
breath. Past medical history was notable solely for tobacco
use (two packs per day for 20 years). There was no history
of hypertension or diabetes and there was no family
history of renal disease. The patient took no prescription
medications but reported taking antacids as needed and
occasional ibuprofen. Physical examination revealed a
heart rate of 92 b.p.m., respiratory rate of 12 breaths
per min, blood pressure of 108/62 mm Hg, and the
absence of edema or cutaneous manifestations.
Laboratory evaluation (Table 1) revealed acute kidney
injury with a creatinine of 7.2 mg/dl, mild hypokalemia,
hypercalcemia, mild hyperphosphatemia,
a severe non-anion gap metabolic alkalosis, and a
suppressed parathyroid hormone level. The patient
reported having not seen a physician for 10 years, and no
baseline laboratory values were available for comparison.
Urinalysis revealed trace protein and a bland sediment
with no red blood cells, white blood cells, or casts. The
patient was found to have a urine protein-to-creatinine
ratio of 0.37 (mg/mg). Serologic evaluation revealed
normal C3 and C4 complement levels and no evidence
of a monoclonal spike on serum or urine protein
electrophoresis. The following serologies were negative:
antinuclear antibody, antineutrophil cytoplasmic
antibody, antistreptolysin O, antiglomerular basement
membrane antibody, hepatitis B surface antigen, and
antihepatitis C antibody. The kidneys measured 9 cm in
length by ultrasound, with increased echogenicity but no
evidence of obstruction. Two discreet areas of dystrophic
calcification were noted within the interpolar region of
the renal parenchyma and measured 6 and 3 mm.
The patient was admitted and given intravenous normal
saline with added potassium for treatment of
hypercalcemia and hypokalemia, antiemetics, and a
proton pump inhibitor. Over the course of 4 days, the
patient’s creatinine declined to 4 mg/dl and serum calcium
and potassium levels normalized. The patient was
discharged.
Following discharge, the patient was feeling well and
the creatinine declined over 2 weeks to 2.3 mg/dl. Five
weeks later, the creatinine was 1.6 mg/dl.
Two months after the initial presentation, repeat serum
chemistries again revealed acute kidney injury with a
creatinine of 5.4 mg/dl. At that time, the patient had a
serum sodium of 134 mmol/l, potassium 2.9 mmol/l,
chloride 75 mmol/l, CO2 44 mmol/l, calcium 12.8 mg/dl,
and phosphorus 6.7 mg/dl. The patient reported no
significant new symptoms although he did mention
persistent ‘heartburn’. On his own, he had discontinued
taking the proton pump inhibitor and restarted antacids,
without relief of symptoms. Similarly, he reported having
to ‘drink milk at night’ to help the symptoms. Physical
examination was unrevealing. Given the unclear
etiology of the patient’s acute kidney injury,
a renal biopsy was performed.
PATHOLOGICAL FINDINGS
The renal biopsy consisted of two cores of renal cortex
containing nine glomeruli, one of which was globally sclerotic.
Glomeruli appeared normal in size and cellularity with patent
capillary lumina and glomerular basement membranes of
normal thickness. Proximal tubules displayed degenerative
changes characterized by luminal ectasia, cytoplasmic simpli-
fication, irregular luminal contours, and prominent nucleoli.
The tubular degenerative changes were accompanied by
prominent intraluminal, intracellular, and interstitial non-
polarizing basophilic calcifications, consistent with calcium
phosphate (Figure 1a–b). The calcium phosphate composition
of the tubular calcifications was confirmed with the von Kossa
stain (Figure 1c). There was mild to moderate tubular atrophy
and interstitial fibrosis involving approximately 30% of the
cortex sampled. There was patchy, mild interstitial inflamma-
tion composed of mainly lymphocytes and associated with
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rare foci of mild tubulitis. Vessels exhibited mild to moderate
arteriosclerosis and arteriolosclerosis with hyalinosis.
Immunofluorescence staining for IgG, IgM, IgA, C3, C1q,
fibrinogen, albumin, and k- and l-light chains was negative.
Electron microscopy revealed intraluminal, intracellular, and
interstitial calcifications. Glomeruli appeared unremarkable,
with minimal foot process effacements and no detectable
electron-dense deposits.
The final diagnosis was an acute and chronic tubulointer-
stitial nephropathy with prominent tubular and interstitial
calcium phosphate deposits, consistent with nephrocalcinosis.
CLINICAL FOLLOW-UP
Following receipt of the renal biopsy results, the patient was
worked up for etiologies of nephrocalcinosis. Upon further
questioning, the patient admitted to daily ingestion of 20–30
Rolaids tablets (calcium carbonate 675 mg per tablet, 220 mg
elemental calcium per tablet) and at least 1 gallon of milk per
day over the past 5–6 years for treatment of reflux symptoms.
He stated that he had previously omitted the excessive
Table 1 | Laboratory results
Laboratory tests Results (normal values)
Sodium 132 mmol/l (135–148 mmol/l)
Potassium 3.2 mmol/l (3.5–5.5 mmol/l)
Chloride 68 mmol/l (96–109 mmol/l)
Bicarbonate 50 mmol/l (20–32 mmol/l)
Blood urea nitrogen 70 mg/dl (5–26 mg/dl)
Creatinine 7.2 mg/dl (0.5–1.5 mg/dl)
Calcium 13.3 mg/dl (8.5–10.6 mg/dl)
Albumin 4.1 g/dl (3.5–5.5 g/dl)
Phosphorus 6.9 mg/dl (2.5–4.5 mg/dl)
Parathyroid hormone o3 pg/ml (12–65 pg/ml)
Hemogram
WBC count 9.4k per ml (4.5–11k per ml)
Hematocrit 39.6% (35.4–44.4%)
Platelet count 456k per ml (150–450k per ml)
Arterial blood gas
pH 7.64 (7.35–7.45)
PaCO2 45 mm Hg (35–45 mm Hg)
PaO2 85 mm Hg (75–100 mm Hg)




Figure 1 | Renal biopsy findings. (a) Low-power view demonstrates tubular atrophy, interstitial fibrosis, interstitial inflammation, tubular
injury, and abundant calcium phosphate deposits (hematoxylin and eosin,  200). (b) At higher magnification, intracellular, intraluminal,
and focal interstitial calcium phosphate deposits are identified (hematoxylin and eosin,  400). (c) Von Kossa stain is positive in the
distribution of the tubular calcifications, confirming the composition as calcium phosphate ( 400).
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antacid and milk intake (which total approximately 10 g
elemental calcium per day) because he thought it was
unrelated to his kidney problem. He also revealed a previous
episode of ‘heartburn’ 1 year prior, at which time he had
been admitted elsewhere with a calcium of 13.2 mg/dl and a
creatinine of 1.5 mg/dl. There was no history of recent
colonoscopy or ingestion of oral sodium phosphate (OSP)
solution.
The patient was instructed to immediately stop using oral
calcium products and markedly reduce milk consumption.
Treatment with pantoprazole was restarted and the patient
was referred to a gastroenterologist for further evaluation and
treatment of symptoms of reflux.
Within 1 month, the symptoms of reflux completely
abated with proton pump inhibitor administration. The
patient discontinued calcium-based antacids, markedly
reduced milk intake, and was compliant with a low-calcium
diet. At 7 months follow-up, the patient has a creatinine of
1.7 mg/dl. On repeated evaluation, serum calcium and
electrolyte levels have remained within the normal range.
FINAL DIAGNOSIS
Nephrocalcinosis due to milk–alkali syndrome (MAS).
DISCUSSION
Nephrocalcinosis is a pattern of renal injury characterized by
abundant renal tubular and interstitial deposits of calcium
phosphate. The calcium phosphate deposits are associated
with varying degrees of acute tubular injury, as well as
chronic, irreversible scarring in the form of tubular atrophy
and interstitial fibrosis. The finding of nephrocalcinosis on
renal biopsy should prompt investigation into conditions
associated with hypercalcemia, including hyperparathyroid-
ism, malignancy, and excessive calcium or vitamin D intake.
Alternatively, nephrocalcinosis may result from exposure
to OSP bowel preparations prior to colonoscopy. The
importance of OSP bowel preparations as a cause of
nephrocalcinosis is underscored by a 2005 series on 31 cases
of nephrocalcinosis from Columbia University, in which
more than 80% of patients with this condition had a history
of recent exposure to OSP.1 The patient in this report denied
exposure to OSP but admitted to significant calcium
carbonate ingestion. The clinical history, presentation, and
biopsy findings are diagnostic of nephrocalcinosis secondary
to MAS.
Milk–alkali syndrome was first described in 19232 as a
toxic reaction to the Sippy treatment of peptic ulcer disease,
which included administration of milk, cream, and a mixture
of bicarbonate-containing powders.3 With the advent of
antisecretory therapies for peptic ulcer disease, the incidence
of MAS declined and was implicated in less than 1% of cases
of hypercalcemia by 1985.4 More recently, a resurgence in
MAS has been seen. One series reported that 12% of patients
presenting with hypercalcemia between 1990 and 1993 were
diagnosed with MAS, making it the third most-common
cause of hypercalcemia (behind hyperparathyroidism and
malignancy).5 Another series examined all 53 cases of MAS
reported from 1983 to 2004.6 The mean age was 50.3 years,
and more than half of the subjects were female. The source of
calcium was calcium carbonate in all of the patients.
Interestingly, only 35.2% of patients were reported as having
milk or dairy products as a major source of calcium, and only
20.4% were hyperphosphatemic. MAS resulted in permanent
renal impairment in 38.8% of patients.6 The cause for the
increase in incidence is not entirely clear but likely involves
increased consumption of calcium carbonate for prevention
or treatment of osteoporosis or dyspepsia. Additional factors
may include the increasingly common practice of adding
calcium to processed foods (such as juices and cereal) and
over-the-counter medications.6
From a pathophysiological standpoint, the two essential
ingredients for development of MAS are the ingestion of
excess calcium along with an absorbable alkali. The amount
of calcium that needs to be consumed to develop the
syndrome varies, but in patients with normal renal function,
greater than 5 g a day is probably needed. However, in
the presence of renal compromise or hyperabsorption of
calcium from the gut, the amount may be much less.7
Increased consumption of calcium and alkali causes an initial
hypercalcemia and alkalosis. Alkalosis leads to increased
tubular reabsorption of calcium. Hypercalcemia directly and
indirectly leads to a reduction in glomerular filtration rate by
causing renal vasoconstriction and decreasing extracellular
volume. Decreased glomerular filtration rate in turn impairs
the kidney’s ability to excrete calcium, and volume depletion
acts as a stimulus for reabsorption of bicarbonate in the
proximal tubule. Hypercalcemia also suppresses parathyroid
hormone levels, which stimulates bicarbonate reabsorption
in the proximal tubule resulting in alkalosis. As such, the
simultaneous presence of hypercalcemia and alkalosis leads to
a vicious cycle in which each abnormality impairs natural
correction of the other.8 A reduction in the ability of the
kidneys to excrete excess calcium is central to the main-
tenance of this disease cycle. More recently, a role for the
calcium-sensing receptor has been suggested in the main-
tenance phase of MAS. Hypercalcemia activates the calcium-
sensing receptor in the thick ascending limb of Henle,
which allows for some increased calcium excretion, but this
excretion is accompanied by natriuresis and diuresis, which
exacerbate volume depletion and therefore prevent efficient
correction of the alkalosis and hypercalcemia.9
The clinical presentation of MAS classically consists of
hypercalcemia, alkalosis, and renal impairment, but pre-
sentation varies greatly depending on the severity and
duration of exposure. Acute toxemia is often characterized
by symptoms including headache, nausea, vomiting, weak-
ness, myalgias, and irritability or apathy. Renal dysfunction
occurs early in the disease, and elevations in blood urea
nitrogen and creatinine are required for the diagnosis. The
urine is often alkaline, but paradoxical aciduria has been
reported.10 Hyperphosphatemia is classically seen because
milk is rich in phosphate. In the modern era, many cases of
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MAS result from ingestion of non-phosphate-containing
forms of calcium, for instance antacids, which contain
calcium carbonate. As such, hypophosphatemia may result
from lower phosphate intake and binding of phosphate in the
gastric lumen by excess calcium.11 In more chronic cases, the
metabolic abnormalities may be essentially asymptomatic,
and patients may come to medical attention for unrelated
problems with incidental findings (such as soft tissue
calcification) that point to the diagnosis of MAS.12 Early
stages with acute toxemia are often reversible, but if the
disease is chronic and has progressed to nephrocalcinosis,
much of the damage may be irreversible.
Diagnostic criteria for MAS include hypercalcemia,
metabolic alkalosis, a history of excessive consumption
of calcium and alkali, and the lack of an alternative etiology
for the laboratory abnormalities (for instance, no evidence of
hyperparathyroidism). It is important to make the diagnosis
of MAS as early as possible to avoid permanent renal damage.
Establishing a diagnosis of MAS requires a high index
of clinical suspicion coupled with a thorough investigation
into medications, dietary supplements, and eating habits
of the patient. MAS should be considered in the differential
diagnosis for all patients with hypercalcemia and metabolic
alkalosis. The two most important diseases in the differential
diagnosis of MAS are hyperparathyroidism and hyper-
calcemia of malignancy. Prompt testing of parathyroid
hormone levels is critical. In patients with MAS who receive
hydration and diuresis as treatment for hypercalcemia,
parathyroid hormone begins to increase within hours of
treatment and may transiently exceed normal levels due to
rebound hypocalcemia, leading to a misdiagnosis of hyper-
parathyroidism.6 Rare causes of hypercalcemia should be
considered in patients without history suggestive of MAS and
without evidence of malignancy or hyperparathyroidism,
including sarcoidosis, tuberculosis, vitamin D intoxication,
Addison’s disease, thyrotoxicosis, and rare familial metabolic
disorders.13
The treatment of MAS conventionally consists of disconti-
nuation of excessive calcium and alkali intake along with
volume repletion. Once normal volume status is restored,
loop diuretics may be used to promote calciuresis. Patients
presenting with acute renal failure may require dialysis.
Treatment with bisphosphonates has been attempted and has
caused significant rebound hypocalcemia in some patients.
Importantly, Picolos et al.14 reported in their series of
11 patients with MAS that treatment with bisphosphonates
was not found to reduce the median duration of hyper-
calcemia when compared with traditional therapy. To avoid
recurrence of the syndrome, patients must be counseled
to avoid calcium supplementation or dyspepsia treatments
that include the combination of calcium and absorbable
alkali. In addition, excess dietary sources of calcium should
be addressed.
In summary, MAS is the third most common cause
of hypercalcemia in non-end-stage renal disease patients,
accounting for 8.8% of cases in a recent series.14 Diagnosis
depends on eliciting a history of excessive calcium intake in
the context of hypercalcemia and metabolic alkalosis.
Prognosis depends on the duration and severity of the
exposure and the degree of renal insufficiency, highlighting
the importance of prompt diagnosis. Treatment is largely
conservative, consisting of cessation of excessive calcium and
alkali intake, hydration, and loop diuretics to promote
calciuresis.
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